Gene therapy for chronic granulomatous disease

Current status and future perspectives

Kerstin B. Kaufmann, Maria Chiriaco, Ulrich Siler, Andrea Finocchi, Janine Reichenbach, Stefan Stein, Manuel Grez

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Several Phase I/II clinical trials aiming at the correction of X-linked CGD by gene transfer into hematopoietic stem cells (HSCs) have demonstrated the therapeutic potential of gene modified autologous HSCs for the treatment of CGD. Resolution of therapy-resistant bacterial and fungal infections in liver, lung and spinal canal of CGD patients were clearly documented in all trials. However, clinical benefits were not sustained over time due to the failure of gene transduced cells to engraft long-term. Moreover, severe adverse effects were observed in some of the treated patients due to insertional mutagenesis leading to the activation of growth promoting genes and to myeloid malignancy. These setbacks fostered the development of novel safety and efficacy improved vectors that have already entered or are about to enter the clinics. Meanwhile, ongoing research is constantly refining the CGD disease phenotype, including the definition of factors that may explain the unique engraftment phenotype observed in CGD gene therapy trials. This review provides a condensed overview on the current knowledge of the molecular pathomechanisms and clinical manifestations of CGD and summarizes the lessons learned from clinical gene therapy trials, the preclinical progress in vector design and the future perspectives for the gene therapy of CGD.

Original languageEnglish
Pages (from-to)447-460
Number of pages14
JournalCurrent Gene Therapy
Volume14
Issue number6
Publication statusPublished - Jan 1 2014

Fingerprint

Chronic Granulomatous Disease
Genetic Therapy
Hematopoietic Stem Cells
Genes
Phenotype
X-Linked Genes
Phase II Clinical Trials
Clinical Trials, Phase I
Spinal Canal
Mycoses
Insertional Mutagenesis
Bacterial Infections
Therapeutics
Safety
Lung
Liver
Growth
Research
Neoplasms

Keywords

  • CGD
  • Clinical trials
  • Engraftment
  • Gene therapy
  • Hyperinflammation
  • NADPH oxidase
  • Primary immunodeficiency
  • ROS

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery
  • Medicine(all)

Cite this

Kaufmann, K. B., Chiriaco, M., Siler, U., Finocchi, A., Reichenbach, J., Stein, S., & Grez, M. (2014). Gene therapy for chronic granulomatous disease: Current status and future perspectives. Current Gene Therapy, 14(6), 447-460.

Gene therapy for chronic granulomatous disease : Current status and future perspectives. / Kaufmann, Kerstin B.; Chiriaco, Maria; Siler, Ulrich; Finocchi, Andrea; Reichenbach, Janine; Stein, Stefan; Grez, Manuel.

In: Current Gene Therapy, Vol. 14, No. 6, 01.01.2014, p. 447-460.

Research output: Contribution to journalArticle

Kaufmann, KB, Chiriaco, M, Siler, U, Finocchi, A, Reichenbach, J, Stein, S & Grez, M 2014, 'Gene therapy for chronic granulomatous disease: Current status and future perspectives', Current Gene Therapy, vol. 14, no. 6, pp. 447-460.
Kaufmann, Kerstin B. ; Chiriaco, Maria ; Siler, Ulrich ; Finocchi, Andrea ; Reichenbach, Janine ; Stein, Stefan ; Grez, Manuel. / Gene therapy for chronic granulomatous disease : Current status and future perspectives. In: Current Gene Therapy. 2014 ; Vol. 14, No. 6. pp. 447-460.
@article{ca484813415446c1a480b284f7b70a2d,
title = "Gene therapy for chronic granulomatous disease: Current status and future perspectives",
abstract = "Several Phase I/II clinical trials aiming at the correction of X-linked CGD by gene transfer into hematopoietic stem cells (HSCs) have demonstrated the therapeutic potential of gene modified autologous HSCs for the treatment of CGD. Resolution of therapy-resistant bacterial and fungal infections in liver, lung and spinal canal of CGD patients were clearly documented in all trials. However, clinical benefits were not sustained over time due to the failure of gene transduced cells to engraft long-term. Moreover, severe adverse effects were observed in some of the treated patients due to insertional mutagenesis leading to the activation of growth promoting genes and to myeloid malignancy. These setbacks fostered the development of novel safety and efficacy improved vectors that have already entered or are about to enter the clinics. Meanwhile, ongoing research is constantly refining the CGD disease phenotype, including the definition of factors that may explain the unique engraftment phenotype observed in CGD gene therapy trials. This review provides a condensed overview on the current knowledge of the molecular pathomechanisms and clinical manifestations of CGD and summarizes the lessons learned from clinical gene therapy trials, the preclinical progress in vector design and the future perspectives for the gene therapy of CGD.",
keywords = "CGD, Clinical trials, Engraftment, Gene therapy, Hyperinflammation, NADPH oxidase, Primary immunodeficiency, ROS",
author = "Kaufmann, {Kerstin B.} and Maria Chiriaco and Ulrich Siler and Andrea Finocchi and Janine Reichenbach and Stefan Stein and Manuel Grez",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "14",
pages = "447--460",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Gene therapy for chronic granulomatous disease

T2 - Current status and future perspectives

AU - Kaufmann, Kerstin B.

AU - Chiriaco, Maria

AU - Siler, Ulrich

AU - Finocchi, Andrea

AU - Reichenbach, Janine

AU - Stein, Stefan

AU - Grez, Manuel

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Several Phase I/II clinical trials aiming at the correction of X-linked CGD by gene transfer into hematopoietic stem cells (HSCs) have demonstrated the therapeutic potential of gene modified autologous HSCs for the treatment of CGD. Resolution of therapy-resistant bacterial and fungal infections in liver, lung and spinal canal of CGD patients were clearly documented in all trials. However, clinical benefits were not sustained over time due to the failure of gene transduced cells to engraft long-term. Moreover, severe adverse effects were observed in some of the treated patients due to insertional mutagenesis leading to the activation of growth promoting genes and to myeloid malignancy. These setbacks fostered the development of novel safety and efficacy improved vectors that have already entered or are about to enter the clinics. Meanwhile, ongoing research is constantly refining the CGD disease phenotype, including the definition of factors that may explain the unique engraftment phenotype observed in CGD gene therapy trials. This review provides a condensed overview on the current knowledge of the molecular pathomechanisms and clinical manifestations of CGD and summarizes the lessons learned from clinical gene therapy trials, the preclinical progress in vector design and the future perspectives for the gene therapy of CGD.

AB - Several Phase I/II clinical trials aiming at the correction of X-linked CGD by gene transfer into hematopoietic stem cells (HSCs) have demonstrated the therapeutic potential of gene modified autologous HSCs for the treatment of CGD. Resolution of therapy-resistant bacterial and fungal infections in liver, lung and spinal canal of CGD patients were clearly documented in all trials. However, clinical benefits were not sustained over time due to the failure of gene transduced cells to engraft long-term. Moreover, severe adverse effects were observed in some of the treated patients due to insertional mutagenesis leading to the activation of growth promoting genes and to myeloid malignancy. These setbacks fostered the development of novel safety and efficacy improved vectors that have already entered or are about to enter the clinics. Meanwhile, ongoing research is constantly refining the CGD disease phenotype, including the definition of factors that may explain the unique engraftment phenotype observed in CGD gene therapy trials. This review provides a condensed overview on the current knowledge of the molecular pathomechanisms and clinical manifestations of CGD and summarizes the lessons learned from clinical gene therapy trials, the preclinical progress in vector design and the future perspectives for the gene therapy of CGD.

KW - CGD

KW - Clinical trials

KW - Engraftment

KW - Gene therapy

KW - Hyperinflammation

KW - NADPH oxidase

KW - Primary immunodeficiency

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=84924807909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924807909&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 447

EP - 460

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 6

ER -